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Abstract
Background/Aim. Management of patients with recur-
rent glioblastoma (GB) comprises a therapeutic challenge
in neurooncology owing to the aggressive nature of the
disease with poor local control despite a combined modal-
ity treatment. The majority of cases recur within the high-
dose radiotherapy field limiting the use of conventional
techniques for re-irradiation due to potential toxicity.
Stereotactic radiosurgery (SRS) offers a viable non-
invasive therapeutic option in palliative treatment of recur-
rent GB as a sophisticated modality with improved setup
accuracy allowing the administration of high-dose, precise
radiotherapy. The aim of the study was to, we report our
experience with single-dose linear accelerator (LINAC)
based SRS in the management of patients with recurrent
GB. Methods. Between 1998 and 2010 a total of 19 pa-
tients with recurrent GB were treated using single-dose
LINAC-based SRS. The median age was 47 (23–65) years
at primary diagnosis. Karnofsky Performance Score was
≥ 70 for all the patients. The median planning target vol-
ume (PTV) was 13 (7–19) cc. The median marginal dose
was 16 (10–19) Gy prescribed to the 80%–95% isodose
line encompassing the planning target volume. The me-
dian follow-up time was 13 (2–59) months. Results. The
median survival was 21 months and 9.3 months from the
initial GB diagnosis and from SRS, respectively. The me-
dian progression-free survival from SRS was 5.7 months.
All the patients tolerated radiosurgical treatment well
without any Common Toxicity Criteria (CTC) grade > 2
acute side effects. Conclusion. Single-dose LINAC-based
SRS is a safe and well- tolerated palliative therapeutic op-
tion in the management of patients with recurrent GB.
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Apstrakt
Uvod/Cilj. Lečenje bolesnika sa recidivantnim glioblastomom
(GB) predstavlja terapijski izazov u neuroonkologiji zbog agresi-
vne prirode bolesti i loše lokalne kontrole, uprkos kombinova-
nom lečenju. Najveći broj bolesnika dobije recidiv, iako prima vi-
sokodoznu radioterapiju u ograničenom predelu. Konvencional-
ne tehnike reiradijacije imaju ograničenu primenu zbog potenci-
jalne toksičnosti. Stereotaksična radiohirurgija (SRH) predstavlja
neinvazivnu terapijsku opciju u palijativnom lečenju rekurentnog
GB kao soficistirani modalitet sa unapređenom preciznošću po-
dešavanja  čime se omogućava primena visokodozne, precizne
radioterapije. Cilj ove studije bio je da se prikažu sopstvena isku-
stva sa primenom jednodozne SRH uz korišćenje linearnog ak-
celeratora (LINAC) u lečenju bolesnika sa rekurentnim GB.
Metode. U periodu od 1998. do 2010. godine lečeno je 19 bole-
snika sa rekurentnim GB korišćenjem linearnog akceleratora za
jednodoznu SRH. Prosečna starost bolesnika pri postavljanju di-
jagnoze bila je 47 (23–65) godina. Karnofsky Performance Score bio je
≥ 70 kod svih bolesnika. Prosečni planirani ciljni volumen (medi-
an planning target volume – PTV) bio je 13 (7–19) cc. Prosečna mar-
ginalna doza iznosila je 16 (10–19) Gy i bila je određena za 80–
95% izodozne linije, ispunjavajući tako planirani ciljni volumen.
Prosečno vreme praćenja bilo je 13 (2–59) meseci. Rezultati.
Prosečno preživljavanje bolesnika iznosilo je 21 mesec, tj. 9,3
meseca od uspostavljanja inicijalne dijagoze GB i primene SRS.
Prosečni interval od SRS do progresije bolesti iznosio je 5,7 me-
seci. Svi bolesnici dobro su podnosili radiohirurško lečenje bez
pojave uobičajenih toksičnih efekata, nabrojanih u kriterijumima
(Common Toxicity Criteria – CTC gradusa > 2) za akutne sporedne
efekte. Zaključak. Jednodozna SRS pomoću linearnog akcelato-
ra bezbedna je i dobro podnošljiva terapijska procedura u lečenju
bolesnika sa rekurentnim GB.
Ključne reči:
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Introduction
Glioblastoma (GB) comprising the most common pri-
mary malignant brain tumor in adults, is as yet considered
an incurable disease with a treatment-refractory, rapidly
progressive course characterized by frequent recurrences
despite a combined modality treatment. Recurrent glio-
blastoma is a more resistant form with a grim diagnosis in
which treatment modalities are used with palliative inten-
tion. Today standard treatment of GB includes surgery fol-
lowed by chemoradiation 
1, 2. Improved survival is achieved
by adding radiotherapy with concurrent and adjuvant temo-
zolomide following surgery 
1, 3, 4, however, most patients
eventually present with recurrence.
Many prognostic factors have been suggested for GB
including age, tumor histopathology, extent of surgery and
performance status. Recursive Partitioning Analysis (RPA)
was applied to all of the prognostic factors to evaluate the
associations between tumor characteristics, patient pre-
treatment factors and treatment, versus survival 
5. Median
survival by RPA classes III, IV, V and VI were 17.9, 11.1,
8.9, and 4.6 months, respectively 
5. This analysis conducted
before the temozolomide era revealed that patients with GB
represented a heterogeneous group with a median duration
of survival ranging from 4.6 to 17.9 months 
5.
Therapeutic options at the time of recurrence include
surgery, radiotherapy and/or chemotherapy 
6, 7, however
these salvage treatment options used with palliative in-
tention are usually hampered by initial primary treatment
with surgery, full course radiotherapy and/or chemother-
apy. Surgery may have a role in providing symptom's
palliation and histopathological verification of recurrrent
disease, but infiltrative nature of GB usualy precludes
optimal surgery at recurrence owing to the risk of signifi-
cant morbidity 
8, 9. Glioblastoma cells are chemoresistant
and modest survival benefit has been achieved with sys-
temic chemotherapy in the setting of recurrent disease 
10–12.
Re-irradiation is a therapeutic option for recurrent GB,
however, the high dose delivered for initial primary dis-
ease releases concerns about radiation induced side ef-
fects in the recurrent disease setting due to the cumulative
dose to normal brain structures with poor repair capacity,
particularly when conventional involved field radiotherapy is
considered 
13. Brachytherapy has been used in the treatment of
recurrent malignant gliomas, but a high morbidity related with
this invasive procedure limits its use 
14, 15. While delivering
tumoricidal doses with conventional radiotherapy tech-
niques is substantially limited by the potential adverse
effects, focal re-irradiation in the form of stereotactic
radiosurgery (SRS) and fractionated stereotactic radio-
therapy (FSRT) exploiting the advantage of rigid immo-
bilization and improved setup accuracy to deliver high
dose of radiation precisely with a steep dose fall-off
around the target are increasingly being used in the re-
current disease setting with promising results 
16–23. In
this study we reported our experience with single-dose
LINAC-based SRS in the management of patients with
recurrent GB.
Methods
Between 1998 and 2010 a total of 19 patients (13 males,
6 females) with recurrent GB were treated using single dose
SRS. All the patients had a diagnosis of glioblastoma con-
firmed histopathologically. The patients were thoroughly
evaluated by a multidisciplinary team consisting of the ex-
perts in radiation oncology, neurosurgery, medical oncology,
and neuroradiology to decide on optimal management. Eligi-
bility criteria for re-irradiation with SRS included the pres-
ence of a contrast-enhancing lesion on T1 weighted MRI of a
suitable size and shape to allow accurate target definition.
All the patients were required to have a Karnofsky Perform-
ance Score (KPS) of ≥ 70 and informed consent. The neuro-
surgical procedure for primary GB was gross-total resection
in 5 patients, subtotal resection in 12 patients and biopsy in 2
patients. Local recurrence was diagnosed by neuroimaging,
which showed regrowth of primary tumor; biopsy or resec-
tion was not required for confirmation. The median age at
initial diagnosis of GB was 47 (23–65) years. Karnofsky Per-
formance Score was ≥ 70 for all the patients, with a median
KPS of 90. Recursive Partitioning Analysis (RPA) classifi-
cation of the 19 patients was Class III in 2 patients, Class IV
in 12 patients and Class V in 5 patients. All the patients re-
ceived first line definitive radiotherapy with a median dose
of 60 (54–62) Gy in daily fractions of 2 Gy. Eleven patients
(57.9%) received chemotherapy consisting of temozolomide
before recurrence. The median time between primary radio-
therapy and SRS was 9 (5–49) months. The most common
presenting symptoms in 15 out of 19 patients at recurrence
included seizures, headache, nausea, vomiting, sensory and
motor deficits.
For the first 10 years, SRS planning was done with
XKnife-3 (Radionics, Boston, MA, USA) planning system
and treatment was delivered with SL-25 LINAC (Elekta,
UK). Radiosurgery planning system was then replaced
with ERGO ++ (CMS, Elekta, US) allowing Volumetric
Modulated Arc Radiosurgery and Synergy LINAC (Elekta,
UK) with 3 mm thickness head-on micro-MLC (micro-
multileaf collimator). On the day of treatment, a stereotac-
tic frame (Leksell frame or 3D-Line frame, Elekta, UK)
was affixed with the help of 4 pins to the patient’s skull
under local anesthesia, and a planning CT scan usually
fused with a prior MRI was used for computerized treat-
ment planning (Figure 1).
Coronal and sagittal images were used in addition to
axial images to further improve target and organ-at-risk
(OAR) delineation accuracy. Target volumes and critical
structures were defined manually by both radiation oncolo-
gist and neurosurgeon. Gross tumor volume (GTV) was de-
fined as contrast-enhancing lesion on T1 weighted MRI. In
the generation of clinical target volume (CTV), GTV was
expanded uniformly in each direction by 3 mm to cover po-
tential microscopic tumor expansion. No additional margin
was added to CTV to generate the planning target volume
(PTV). Most often defined critical structures included the
brainstem, optic chiasm and optic nerves, whereas dose con-
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A single 360° arc, double 360° arcs, or five 180° arcs
were selected to spare the critical structures around the target
location in the planning. Arc Modulation Optimization Algo-
rithm (AMOA) was used to improve target coverage while
sparing critical structures. Among different candidate treat-
ment plans, the best plan was selected according to dose-
volume histogram data analysis.
All the patients underwent single dose SRS using a LI-
NAC with 6-MV photons. The median PTV was 13 (7–19)
cc. The median marginal dose was 16 (10–19) Gy prescribed
to the 80%–95% isodose line encompassing the PTV. Iso-
centers of all the patients were checked by kV-CBCT (kilo-
voltage Cone Beam Computed Tomography) and setup veri-
fications were done by XVI (X-ray Volumetric Imaging,
Elekta, UK) system. Eight milligrams of intravenous dexa-
methasone with H2-antihistamines was used immediately
after SRS.
After the completion of the treatment, follow-up visits
were scheduled for every patient routinely at the first 2-month
and then at 3-month intervals including clinical examination
with neurological evaluation and neuroimaging with contrast-
enhanced MRI. The patients were requested to inform the
treating physician about any unexpected neurological wors-
ening regardless of the follow-up schedule. Macdonald criteria
were used to assess response to radiosurgical treatment 
24.
Complete response was defined as no clinically detectable
cancer following treatment. Partial response was defined as ≥
50% reduction in the size of enhancing tumor. Progressive
disease was defined as ≥ 25% increase in the size of enhancing
tumor or appearance of new lesions. If enhancing lesion did
not meet the criteria for complete response, partial response, or
progressive disease, then response was defined as stable dis-
ease. Local tumor control was calculated regarding complete
or partial response and stable disease. If radiation necrosis was
suspected, additional procedures such as MR-spectroscopy
were scheduled. Acute toxicity was scored according to the
Common Toxicity Criteria (CTC). The median follow-up time
was 13 (2–59) months. Endpoints of the study were overall
survival (OS) and progression-free survival (PFS). Overall
survival was calculated from primary GB diagnosis and sur-
vival after SRS was calculated from the date of SRS. Progres-
sion-free survival was calculated from the date of SRS until
progression of tumor or death.
Results
The characteristics of the patients are shown in Table 1.
The median overall survival was 21 (6.1–58.8) months
from diagnosis of primary GB. The median progression-free
survival was 5.7 (1–49.7) months and overall survival was
9.3 (1.1–49.7) months after SRS.
Table 1
Characteristics of the patients with recurrent glioblastoma
Patients characteristics (n = 19) n %
Gender
male
female
13
6
68
32
Age at primary diagnosis of glioblastoma
 ≤ 50 years
 > 50 years
12
7
63
37
Histologic diagnosis
 WHO grade IV glioblastoma 19 100
Neurosurgical procedures
 gross-total resection
 subtotal resection
 biopsy
5
12
2
26
63
11
KPS
 90–100
 80
 70
9
8
2
47
42
11
RPA classification
 class III
 class IV
 class V
2
12
5
11
63
26
KPS – Karnofsky Performance Score; RPA – Recursive Partitioning Analysis
All the patients tolerated the treatment well with no
acute toxicities (> CTC grade 2). Headache, nausea and
vomiting were observed in 3 patients (15.8%), which re-
solved after 3 weeks of steroid therapy. Magnetic resonance
imaging of these patients 2 months after SRS at first follow-
up revealed stable disease. The first follow-up MRI at 2
Fig. 1 – Treatment planning of a patient with recurrent glioblastoma in axial planning computerized tomography in ERGO
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months after SRS revealed partial response in 1 patient
(5.3%), stable disease in 14 patients (73.7%) and progressive
disease in 4 patients (21%). Local tumor control was
achieved in 15 out of 19 patients (79%) and median duration
of response was 7 months. Tumor progression was the cause
of death in all the patients during follow-up.
Discussion
Glioblastoma, the most common primary brain tumor in
adults, is characterized by rapid progression and has a grim
prognosis with the median survival of 12–18 months despite
multidisciplinary management with surgery, radiotherapy
and chemotherapy at primary diagnosis 
25. Management of
GB is mainly palliative since providing cure for this devas-
tating tumor is almost unachievable. Most patients eventually
present with local recurrence
 and die as a result of locally re-
current disease within the original tumor site 
26–29. Therapeu-
tic options at the time of recurrence include surgery, systemic
therapy, re-irradiation and investigational treatment modalities.
Surgery for repeat debulking of recurrent tumor may be con-
sidered. Carmustine wafers have also been used after reopera-
tion for recurrent gliomas with promising results 
30. However,
surgical treatment is usually hampered by the infiltrative na-
ture of GB, which frequently precludes optimal re-resection
8, 9. Modest survival benefit has been achieved with systemic
chemotherapy in the setting of recurrent disease 
10–12. Sys-
temic therapy agents used in recurrent GB include temo-
zolomide with various dosing regimens, antiangiogenic
agents such as bevacizumab which may be used in combina-
tion with irinotecan, nitrosoureas either as single agents or in
combination regimens; however, optimal combination of
systemic agents has yet to be defined and currently consid-
ered experimental. Brachytherapy has been used in the
treatment of recurrent malignant gliomas, but needs surgical
intervention, which may cause severe morbidity 
14, 15.
Re-irradiation using conventional techniques at recur-
rence is usually limited by the high dose delivered for initial
primary disease. Cumulative dose to normal brain structures
with poor repair capacity should be thoroughly assessed to
avoid excess neurotoxicity when considering re-irradiation.
Among the radiotherapeutic options considered for re-
irradiation of recurrent GB, radiosurgery appears to be the
most appealing treatment modality. Its capability to precisely
deliver tumoricidal doses of irradiation in a single fraction of-
fering a non-invasive, well tolerated treatment with a steep
dose fall-off around the target location minimizing normal tis-
sue exposure to avoid toxicity without any systemic side ef-
fects is the reason for selecting SRS as a viable therapeutic
option. Utilizing sophisticated stereotactic techniques offer
non-invasive high dose treatments with submillimeter geomet-
ric accuracy through rigid immobilization and improved setup
accuracy. Stereotactic radiosurgery may be considered as a vi-
able therapeutic option in the management of recurrent GB
with its inherent advantages over other radiotherapeutic ap-
proaches, however, selecting eligible patients to be treated
with this highly sophisticated technology requires thorough as-
sessment. Lesion size and shape should be suitable for SRS to
allow accurate target definition. Infiltrative nature of glioblas-
tomas limit the use of focal treatments owing to potential mi-
croscopic extension of the disease beyond radiological borders
thus making target definition difficult, so utmost care should
be focused on patient selection for re-irradiation with SRS.
In our study, the patients were thoroughly evaluated by
a multidisciplinary team before deciding on optimal man-
agement. All the patients in our study tolerated the treatment
well with no acute toxicities (> CTC grade 2). We used a 3
mm uniform margin around the contrast-enhancing lesion on
T1 weighted MRI to cover potential microscopic expansion
of the recurrent tumor. Maranzano et al. 
18 also used a 3 mm
margin in their study. In the RTOG 0023 study by Cardinale
et al.
 31, PTV for stereotactic radiotherapy included the GTV
plus a 5 mm margin in all directions. In the study by Fogh et
al.
 22 and Souhami et al.
 32, no margin was used in target defi-
nition. There is still no consensus on the use of margins for
target definition in SRS of glioblastomas.
Most recurrences occur locally in patients with GB re-
gardless of the initial management strategy 
26–29. Failure to
control the tumor at its original site has prompted the utiliza-
tion of SRS in an attempt to achieve dose escalation in pri-
mary radiotherapy of GB, however, no improvement in over-
all survival was achieved 
32. In the recurrent setting, retro-
spective data with matched pair analyses suggest the benefit
of salvage therapy although results are subject to selection
bias favoring patients undergoing salvage 
33. Stereotactic ra-
diosurgery has been used to palliate GB recurrences with
promising results 
16–23, 34–36. In the case control study by Ma-
hajan et al. 
16, the median survival was 11 months in the case
group and 10 months in the control group from the date of
SRS. In the study by Shrieve et al. 
17, the median actuarial
survival was 10.2 months for patients treated with SRS from
the time of treatment for recurrence. In a recent study by Ma-
ranzano et al. 
18, the median overall survival from the first
surgery to death was 26 months, median overall survival after
re-irradiation was 11 months, the median progression-free
survival was 4 months while local control was obtained in
71% of patients. In the study by Hsieh et al.
 19, treatment with
adjuvant gamma knife-SRS conferred a median overall sur-
vival of 14.3 months for the patient cohort. Adjuvant gamma
knife-SRS performed at tumor progression yielded an im-
proved median survival of 16.7 months compared with the
median survival of 10 months when SRS was performed up-
front after initial tumor resection 
19. In the study by Combs et
al.
 20, the median overall survival was 21 months and 8
months after primary diagnosis and after re-irradiation, re-
spectively for patients treated with fractionated stereotactic
re-irradiation for GB. In the study by Kong et al.
 21, the me-
dian overall survival was 23 months and median progression-
free survival after SRS was 4.6 months for patients with GB.
Compared with the historical control group, SRS was found
to prolong survival significantly as a salvage treatment in pa-
tients with recurrent glioblastoma (23 months vs 12 months;
p < 0.0001)
 21. In the study by Fogh et al.
 22, the median sur-
vival time (MST) from the date of diagnosis and from the
time of hypofractionated stereotactic radiation therapy (H-
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with GB. Follow-up MRI scans after H-SRT revealed stable
disease in 60% of the patients, minimal response in 10% of
the patients, and progression in 30% of the patients 
22. In the
study by Patel et al. 
23, MST after SRS was 8.5 months. Ra-
diographic tumor response or stable disease was observed in
35% of patients and tumor progression was seen in 65% of
patients treated with SRS 
23. In the study by Cho et al.
34 com-
paring single dose vs fractionated stereotactic radiotherapy for
recurrent high grade gliomas, actuarial MST was 11 months
for the SRS group and 12 months for the FSRT group, with-
out a statistical significance. In the study by Hall et al.
 35
evaluating the role of SRS in the management of recurrent
malignant gliomas, the actuarial survival time for all patients
was 21 months from diagnosis and 8 months from radiosur-
gery. In the study by Combs et al.
 36, the median overall sur-
vival was 22 months and 10 months from primary diagnosis
and after SRS, respectively for patients with recurrent GB.
In our study, the median overall survival was 21 months
from diagnosis of primary GB. The median progression-free
survival was 5.7 months and overall survival was 9.3 months
after SRS. The first follow-up MRI at 2 months after SRS
revealed a partial response in 1 patient (5.3%), stable disease
in 14 patients (73.7%) and progressive disease in 4 patients
(21%); thus local tumor control was achieved in 15 out of 19
patients (79%). Tumor progression was the cause of death
for all the patients during the follow-up in our study.
Conclusion
LINAC-based, single-dose SRS, is a safe and well-
tolerated palliative therapeutic option in the management of
patients with recurrent GB. Further studies are warranted to
refine the optimal management of this challenging, as yet in-
curable disease.
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